• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Covid-19: Remdesivir is recommended for authorisation by European Medicines Agency.

作者信息

Wise Jacqui

机构信息

London.

出版信息

BMJ. 2020 Jun 29;369:m2610. doi: 10.1136/bmj.m2610.

DOI:10.1136/bmj.m2610
PMID:32601048
Abstract
摘要

相似文献

1
Covid-19: Remdesivir is recommended for authorisation by European Medicines Agency.新冠病毒-19：欧洲药品管理局建议批准瑞德西韦。
BMJ. 2020 Jun 29;369:m2610. doi: 10.1136/bmj.m2610.
2
Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.在东南欧国家授予药品营销许可：主管当局的观点。
Regul Toxicol Pharmacol. 2010 Jul-Aug;57(2-3):325-32. doi: 10.1016/j.yrtph.2010.04.001. Epub 2010 Apr 10.
3
Marketing authorisation applications submitted to the European Medicines Agency by small and medium-sized enterprises: an analysis of major objections and their impact on outcomes.中小企业向欧洲药品管理局提交的营销授权申请：主要异议分析及其对结果的影响。
Drug Discov Today. 2018 Oct;23(10):1801-1805. doi: 10.1016/j.drudis.2018.06.018. Epub 2018 Jun 25.
4
Medicines under additional monitoring in the European Union.欧盟额外监测的药品。
Farm Hosp. 2019 Jan 1;43(1):19-23. doi: 10.7399/fh.11041.
5
European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.欧洲药品管理局对上市后研究的审查及其对欧洲药物流行病学和药物警戒中心网络的影响。
Pharmacoepidemiol Drug Saf. 2011 Oct;20(10):1021-9. doi: 10.1002/pds.2209.
6
[Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].[癌症：真的如此不同吗？从药品监管机构的角度看肿瘤药物的特殊性]
Z Evid Fortbild Qual Gesundhwes. 2013;107(2):120-8. doi: 10.1016/j.zefq.2013.02.003. Epub 2013 Apr 4.
7
Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.提高上市后研究的科学标准、独立性和透明度：欧洲药物流行病学和药物警戒中心网络的作用。
Pharmacoepidemiol Drug Saf. 2012 Jul;21(7):690-696. doi: 10.1002/pds.3281. Epub 2012 Apr 23.
8
The licensing of medicines in the UK.英国药品的许可情况。
Drug Ther Bull. 2009 Apr;47(4):45-8. doi: 10.1136/dtb.2009.03.0012.
9
Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.欧盟《儿童用药规例》下临床试验完成和结果报告的延误：一项队列研究。
PLoS Med. 2018 Mar 1;15(3):e1002520. doi: 10.1371/journal.pmed.1002520. eCollection 2018 Mar.
10
Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.欧洲药品评估局批准的儿童用药。
Eur J Clin Pharmacol. 2002 Nov;58(8):495-500. doi: 10.1007/s00228-002-0511-0. Epub 2002 Sep 25.

引用本文的文献

1
Remdesivir Effectiveness in Reducing the Risk of 30-Day Readmission in Vulnerable Patients Hospitalized for COVID-19: A Retrospective US Cohort Study Using Propensity Scores.瑞德西韦对降低COVID-19住院脆弱患者30天再入院风险的有效性：一项使用倾向评分的美国回顾性队列研究。
Clin Infect Dis. 2024 Dec 13;79(Suppl 4):S167-S177. doi: 10.1093/cid/ciae511.
2
Assessing Genomic Mutations in SARS-CoV-2: Potential Resistance to Antiviral Drugs in Viral Populations from Untreated COVID-19 Patients.评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）中的基因组突变：来自未经治疗的2019冠状病毒病（COVID-19）患者病毒群体中对抗病毒药物的潜在耐药性
Microorganisms. 2023 Dec 19;12(1):2. doi: 10.3390/microorganisms12010002.
3
Effectiveness and Controversy of Convalescent Plasma Therapy for Coronavirus Disease 2019 Patients.
2019冠状病毒病患者恢复期血浆治疗的有效性与争议
Infect Dis Immun. 2021 Dec 2;2(1):49-54. doi: 10.1097/ID9.0000000000000033. eCollection 2022 Jan.
4
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.新型冠状病毒肺炎（COVID-19）治疗方法：旧药新用的临床应用及基于靶点的药物发现的未来策略
Genes Dis. 2023 Jul;10(4):1402-1428. doi: 10.1016/j.gendis.2022.12.019. Epub 2023 Apr 7.
5
Green Approach Toward Triazole Forming Reactions for Developing Anticancer Drugs.绿色方法用于三唑形成反应以开发抗癌药物。
Curr Org Synth. 2024;21(4):380-420. doi: 10.2174/1570179420666230508125144.
6
Carbohydrate-based drugs launched during 20002021.2000年至2021年期间推出的碳水化合物类药物。 （你提供的原文“20002021”表述有误，推测应该是“2000 - 2021” ）
Acta Pharm Sin B. 2022 Oct;12(10):3783-3821. doi: 10.1016/j.apsb.2022.05.020. Epub 2022 May 23.
7
Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Regimens in Hospitalized Patients in Shiraz.设拉子住院患者中 COVID-19 治疗方案的成本与结果评估
Iran J Sci Technol Trans A Sci. 2022;46(5):1339-1347. doi: 10.1007/s40995-022-01351-0. Epub 2022 Sep 15.
8
Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far.严重急性呼吸综合征冠状病毒、中东呼吸综合征冠状病毒和严重急性呼吸综合征冠状病毒2感染的经验教训：我们目前所了解的情况。
Can J Infect Dis Med Microbiol. 2022 Aug 12;2022:1156273. doi: 10.1155/2022/1156273. eCollection 2022.
9
Ultraviolet-coupled advanced oxidation processes for anti-COVID-19 drugs treatment: Degradation mechanisms, transformation products and toxicity evolution.紫外线耦合高级氧化工艺处理抗 COVID-19 药物：降解机制、转化产物和毒性演变。
Chemosphere. 2022 Sep;303(Pt 1):134968. doi: 10.1016/j.chemosphere.2022.134968. Epub 2022 May 14.
10
Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States.美国2019冠状病毒病住院患者的临床管理
Open Forum Infect Dis. 2021 Sep 28;9(1):ofab498. doi: 10.1093/ofid/ofab498. eCollection 2022 Jan.